https://www.live-feeds.com/feed/kyverna-resetting-conversation-with-1-year-miv-cel-data-as-autoimmune-car-t-peers-hit-safety-snagsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/kyverna-resetting-conversation-with-1-year-miv-cel-data-as-autoimmune-car-t-peers-hit-safety-snagshttps://www.live-feeds.com/feed/kyverna-resetting-conversation-with-1-year-miv-cel-data-as-autoimmune-car-t-peers-hit-safety-snags#u85653Sat, 26 Sep 2026 23:50:28 +0000Kyverna Therapeutics has released one-year data for its CAR-T therapy, miv-cel, demonstrating drug-free remission and a strong safety profile in patients with generalized Myasthenia Gravis (gMG) and Stiff Person Syndrome (SPS). The company intends to use this long-term durability data to support its FDA submission. Kyverna aims to complete a Biologics License Application (BLA) for the treatment of Stiff Person Syndrome within the current year, positioning itself to potentially secure the first FDA-approved CAR-T therapy for an autoimmune condition.Why it mattersCAR-T therapies were originally